BEXSERO is an FDA-approved vaccine to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

BEXSERO may not protect all individuals.

BEXSERO is the ONLY meningitis B vaccine that can be completed in as fast as 1 month with just 2 doses

Help protect your teen against meningitis B.

Talk to your healthcare professional about vaccination with BEXSERO.


There are two different types of meningitis vaccines recommended. The meningitis vaccine people may have received when they were younger covered meningitis ACWY, not meningitis B. That's because a meningitis B vaccine wasn't available until 2014.

BEXSERO is a vaccine approved to help prevent meningitis B.

Increased rates.

16- to 23-year-olds have increased rates of meningitis B

Uncommon but can be fatal.

About 10-15 out of 100 people infected with meningitis B will die, sometimes within 24 hours

Unpredictable & moves quickly.

Meningitis B usually strikes without warning

Need reminders for the second dose of BEXSERO?

It’s important to get both doses of BEXSERO. Sign up for GSK’s 2nd Dose Reminder Service for Meningitis B. You’ll get text message reminders to help you remember to schedule your or your teen’s next appointment and get the 2nd dose.